| Literature DB >> 32883417 |
Khaled M Abdelrahman1, Marcus Y Chen1, Amit K Dey1, Renu Virmani2, Aloke V Finn2, Ramzi Y Khamis3, Andrew D Choi4, James K Min5, Michelle C Williams6, Andrew J Buckler7, Charles A Taylor8, Campbell Rogers8, Habib Samady9, Charalambos Antoniades10, Leslee J Shaw5, Matthew J Budoff11, Udo Hoffmann12, Ron Blankstein13, Jagat Narula14, Nehal N Mehta15.
Abstract
Evaluation of coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) has seen a paradigm shift in the last decade. Evidence increasingly supports the clinical utility of CCTA across various stages of CAD, from the detection of early subclinical disease to the assessment of acute chest pain. Additionally, CCTA can be used to noninvasively quantify plaque burden and identify high-risk plaque, aiding in diagnosis, prognosis, and treatment. This is especially important in the evaluation of CAD in immune-driven conditions with increased cardiovascular disease prevalence. Emerging applications of CCTA based on hemodynamic indices and plaque characterization may provide personalized risk assessment, affect disease detection, and further guide therapy. This review provides an update on the evidence, clinical applications, and emerging technologies surrounding CCTA as highlighted at the 2019 National Heart, Lung and Blood Institute CCTA Summit. Published by Elsevier Inc.Entities:
Keywords: atherosclerosis; coronary artery disease; coronary computed tomography angiography
Mesh：
Year: 2020 PMID： 32883417 PMCID： PMC7480405 DOI： 10.1016/j.jacc.2020.06.076
Source DB: PubMed Journal: J Am Coll Cardiol ISSN： 0735-1097 Impact factor: 24.094